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Werner protein (WRN) plays an important role in DNA repair, replication, transcription and consequently 
genomic stability via its DNA-helicase and exonuclease activity. Loss of function of WRN is associated with 
Werner syndrome (WS) which is characterised by premature aging and cancer predisposition. Malignancies that 
are commonly linked to WS are thyroid carcinoma, melanoma, breast cancer, meningioma, soft tissue and bone 
sarcomas. Currently, the clinicopathological significance of WRN in sporadic breast cancer is largely unknown. 
Methods  
We investigated the clinicopathological significance of WRN protein expression in invasive sporadic breast 
cancers in the Nottingham series comprising of two cohorts (n=1902). We correlated WRN protein expression to 
clinicopathological characteristics, DNA repair protein expression and survival outcomes. 
Results 
There is strong evidence of association between low WRN nuclear and cytoplasmic co-expression and low levels 
of KU70/KU80, DNA-PK, DNA Pol-B, CKD18, cytoplasmic RECQL4 and nuclear BLM protein expression 
(adjusted p-values <0.05). Tumours with low nuclear or cytoplasmic WRN expression have worse overall breast 
cancer-specific survival (BCSS) (adjusted p-values <0.05). In Topoisomerase I overexpressed tumours, low WRN 
nuclear expression was associated with poor BCSS (p-value <0.05). Interestingly, there was no evidence 
association between WRN protein expression and clinicopathological parameters (p-values>0.05).  
Conclusions  
Low WRN protein expression is associated with poor BCSS in patients with sporadic breast cancer. This can be 





Werner (WRN) enzyme, also known as Recombinase Q like helicase 2 (RECQL2), has a DNA-helicase and 
exonuclease activity towards double-stranded DNA [1, 2]. The gene which encodes WRN protein is located in 
chromosome 8p12 and its role is to unwind the DNA and remove abnormal structures in an ATP-dependent and 
directionally specific manner [1, 3, 4]. WRN protein has been shown to play an important role in DNA repair, 
replication, transcription, telomere maintenance and consequently genomic stability [1, 5, 6]. WRN co-localizes 
and shows direct interaction with TOPO I. WRN enhances the ability of TOPO I to relax negatively supercoiled 
DNA [7]. 
Mutations in the human WRN gene leading to the loss of WRN gene product are associated with Werner syndrome 
(WS) [3]. WS is a rare autosomal recessive disease that is characterized by chromosomal instability, premature 
aging, and propensity to malignancies [1, 8]. The most common neoplasms in patients with WS are soft tissue 
sarcoma, osteosarcoma, thyroid cancer, malignant melanoma, breast cancer, benign meningioma and myeloid 
disorders [8]. Frequent molecular alterations that are seen in WS include nonsense, splicing or frameshift 
mutations, extensive deletions, inversions and reciprocal translocations with missense mutations being uncommon 
[9-11].  
RECQ helicases have a highly conserved RECQ C-terminal group that interacts with DNA damage response 
proteins [1, 12, 13]. Knockout of WRN in primary fibroblasts using RNA interference led to increased oxidative 
DNA damage and early cellular senescence indicating that WRN regulates oxidative stress homeostasis and DNA 
repair [14].  This was supported by Opresko et. al who demonstrated that deletion of WRN resulted in growth 
arrest at G2/M cell cycle phases, DNA damage and increased tumour cell death rate [12]. Additionally, the 
surviving proliferative clones overexpressed WRN protein which indicates that WRN plays an important role not 
only in carcinogenesis but also in tumour growth [15].  
To date, there is no clear evidence about the clinicopathological significance of WRN protein in sporadic breast 
cancer.  In this study, we investigated the clinicopathological significance of WRN protein expression in patients 




Tissue culture and Western blot analysis 
Western blot analysis was used to evaluate the specificity of anti-WRN antibody, before using them for 
immunohistochemistry (IHC). WRN protein expression was assessed in four breast cancer cell lines MCF7, 
MDA-MB-231, MDA-MB-436, and MDA-MB-468. Cell lines were purchased from American Type Culture 
Collection (ATCC, Manassas, USA). MDA-MB-436 and MDA-MB-468 cells were cultured in minimum 
essential amino acids medium supplemented with 1% L-glutamine and 1% non-essential amino acids. MCF-7  
and MDA-MB-231 cells were grown in RPMI medium. All media were supplemented with 10% FBS and 1% 
penicillin streptomycin. Protein samples were prepared by lysing cells in RIPA buffer (Sigma–Aldrich) containing 
protease inhibitor (Sigma) and phosphatase inhibitor cocktail 1 and 2 (Sigma). Samples were run on SDS-PAGE 
gel (4–12%) bis-tris. The antibody used was anti-WRN rabbit polyclonal antibody (Novus Biological, cat.no 
NBP1-87143) at 1:1500 dilution. Protein detection and quantification were determined by scanning the 
membranes on Licor-Odyssey’s Scanner (Licor, Biosciences) at the predefined intensity fluorescence. 
Patient selection for protein data 
Comprehensive evaluation of the protein expression of WRN in breast cancer was performed in two breast cancer 
patient cohorts. The first cohort consisted of 1650 primary invasive breast carcinomas who were diagnosed 
between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series. Patient 
demographics are summarised in Supplementary Tables S1 and S2. This is a well-characterised series of patients 
with long-term follow-up that have been investigated in a wide range of biomarker studies [16-18]. All patients 
were treated in a uniform way in a single institution with standard surgery (mastectomy or wide local excision), 
followed by Radiotherapy. Prior to 1989, patients did not receive systemic adjuvant treatment (AT). After 1989, 
AT was scheduled based on prognostic and predictive factor status, including Nottingham Prognostic Index (NPI), 
oestrogen receptor-α (ER-α) status, and menopausal status. Patients with NPI scores of < 3.4 (low risk) did not 
receive AT. In pre-menopausal patients with NPI scores of ≥ 3.4 (high risk), classical Cyclophosphamide, 
Methotrexate, and 5-Fluorouracil (CMF), chemotherapy was given; patients with ER-α-positive tumours were 
also offered endocrine therapy. Postmenopausal patients with NPI scores of ≥ 3.4 and ER-α positivity were offered 
endocrine therapy, while ER-α-negative patients received classical CMF chemotherapy. Median follow-up was 
111 months (range 1–233 months). Survival data, including breast cancer-specific survival (BCSS), disease-free 
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survival (DFS), and development of loco-regional and distant metastases (DM), were maintained on a prospective 
basis. Disease-free survival was defined as the number of months from diagnosis to the occurrence of local 
recurrence, local lymph node (LN) relapse or DM relapse. Breast cancer-specific survival (BCSS) was defined as 
the number of months from diagnosis to the occurrence of BC-related death.  Local recurrence-free survival (LRS) 
was defined as the number of months from diagnosis to the occurrence of local recurrence. DM-free survival was 
defined as the number of months from diagnosis to the occurrence of DM relapse. Survival was censored if the 
patient was still alive at the time of analysis, lost to follow-up, or died from other causes. 
The second cohort was an independent series of 252 ER-negative primary invasive breast cancers diagnosed and 
treated at Nottingham University Hospitals between 1999 and 2007. All patients were primarily treated with 
surgery, followed by Radiotherapy and anthracycline chemotherapy.  
Ethical approval was obtained from the Nottingham Research Ethics Committee (Reference number C202313). 
Tumour Marker Prognostics Studies (REMARK) criteria, recommended by McShane et al [19], were followed 
throughout this project. 
Tissue microarray and immunohistochemistry 
Breast tumours were arrayed in tissue microarrays (TMAs) constructed with two replicate 0.6 mm cores from the 
centre and periphery of the tumours. Optimal concentration and conditions for staining were ascertained for WRN 
antibody using the Thermo Scientific Shandon Sequenza chamber system (REF: 72110017), in combination with 
the Novolink Max Polymer Detection System (RE7280-K: 1250 tests), and the Leica Bond Primary Antibody 
Diluent (AR9352), each used according to the manufacturer’s instructions (Leica Microsystems). Leica 
Autostainer XL machine was used to dewax and rehydrate the slides. The WRN antibody (Rabbit Antibody, 
polyclonal) was purchased from Novus Biological (NBP1-87143). Pre-treatment antigen retrieval was performed 
on the TMA sections using sodium citrate buffer (pH 6.0) and heated for 20 min at 95 °C in a microwave 
(Whirlpool JT359 Jet Chef 1000W). A set of slides were incubated at 18 h at room temperature at a dilution of 
1:100. Negative and positive (by omission of the primary antibody and IgG matched serum) controls were 
included in each run. The negative control ensured that all the staining was produced from the specific interaction 
between antibody and antigen. 
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Evaluation of immune staining 
The tumour cores were evaluated by AA and an expert pathologist blinded to the clinicopathological 
characteristics of patients. Whole field inspection of the core was scored and intensities of nuclear and cytoplasmic 
staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. 
The percentage of each category was estimated (0–100%). H-score (range 0–300) was calculated by multiplying 
intensity of staining and percentage staining. Not all cores within the TMA were suitable for IHC analysis as some 
cores were missing or lacked tumour (<15% tumour). As our data were non-parametric, we used median cut off 
to dichotomise H score expression of WRN into low and high expression. A median H score of ≥ 116 was taken 
as the cut-off for high WRN nuclear expression and a median H-score of ≥20 was taken as cut off for high WRN 
cytoplasmic expression. 
Statistical analysis  
Data analysis was performed using SPSS (SPSS, version 22 Chicago, IL). Where appropriate, Pearson’s Chi-
square, Fisher’s exact, Student’s t and ANOVA one-way tests were used. Cumulative survival probabilities were 
estimated using the Kaplan–Meier method, and differences between survival rates were tested for significance 
using the log-rank test. Multivariate analysis for survival was performed using the Cox proportional hazard model. 
The proportional hazards assumption was tested using standard log–log plots. Hazard ratios (HR) and 95% 
confidence intervals (95% CI) were estimated for each variable. All tests were two-sided with a 95% CI and a p 
value < 0.05 considered significant. For multiple comparisons, p values were adjusted according to Holm-
Bonferroni correction method [20]. 
Results 
WRN protein expression in breast cancer 
We initially assessed WRN protein expression in a panel of breast cancer cell lines to confirm the specificity of 
antibodies for IHC in the current study. As shown in Figures 1A and 1B, the anti-WRN antibody was not only 
specific but also showed that MCF-7, MDA-MB231, MDA-MB-436, and MDA-MB-468 have a robust expression 
of WRN protein. In contrast, MDA-MB-436 has the least WRN expression. We then proceeded to WRN protein 
levels in clinical breast carcinoma samples. 
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WRN nuclear expression in tumour tissue is lower than normal breast tissue  
We also evaluated the expression of WRN protein in 20 tumour-associated normal breast tissue slides. We 
observed both nuclear and cytoplasmic localisation of WRN in normal and tumour breast tissue. (Figure 1C). We 
also observed that WRN nuclear expression was lower in tumour tissue (Mean H-Score = 116) as compared to 
normal breast tissue (Mean H score = 220). For WRN cytoplasmic expression, in tumour tissue mean H score was 
20 as compared to a mean H score of 170 in normal breast tissue (Figure 1D). 
WRN nuclear expression is associated with other DNA repair proteins but not with clinicopathological 
features in breast cancer  
A total of 720 tumours were suitable for WRN protein expression analyses. There was no statistically significant 
association between WRN nuclear expression and clinicopathological features in breast cancer (Table 1). 
However, when we correlated WRN nuclear expression to other DNA repair protein and regulators, low nuclear 
WRN was significantly associated with low  KU70/KU80 levels (p=0.039), low DNA PKc (p=0.019), low 
cytoplasmic FEN1 (p=0.016) and low DNA Pol-b (p=0.019). In addition, reduced WRN protein expression was 
associated with low CDK18 levels (p=0.015). There was also a strong association with low expression levels of 
other DNA helicases such as nuclear and cytoplasmic RECQL4 (p values<0.05), and RECQL5 (p=0.013). 
WRN cytoplasmic expression is not associated with clinicopathological features in breast cancer  
There was no statistically significant association between WRN cytoplasmic expression and clinicopathological 
features in breast cancer (Table 2). However, when we correlated WRN cytoplasmic expression to other DNA 
repair protein and regulators, low nuclear WRN cytoplasmic was significantly associated with low DNA PKc 
(p=0.039) and low nuclear BLM (p=0.026). 
WRN nuclear and cytoplasm co-expression is associated with impaired DNA repair and cell cycle 
regulation 
15.4% of tumours had low nuclear/high cytoplasmic expression, 30.4% of tumours had low nuclear/low 
cytoplasmic expression, 36% of tumours had high nuclear/high cytoplasmic expression and 18.2% of tumours 
demonstrated high nuclear/low cytoplasmic expression. 
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When we combined the nuclear and cytoplasmic expression of WRN protein, low cytoplasmic and nuclear co-
expression of WRN protein was statistically associated with an aggressive molecular phenotype. Specifically, 
there was strong evidence of association between low WRN nuclear and cytoplasmic co-expression and low levels 
of KU70/KU80 (p=0.004), DNA-PK (p=0.003), DNA Pol-B (p=0.05), CKD18 (p=0.029), cytoplasmic RECQL4 
(p=0.031), and nuclear BLM protein expression (p=0.044) (Table 3). 
These results suggests that low WRN protein expression is associated with impaired DNA repair and cell cycle 
regulation in patients with sporadic breast cancer. 
WRN nuclear and TOPO1 co-expression is not associated with clinicopathological features in breast cancer 
As discussed previously WRN interacts with TOPO1 and enhances the ability of TOPO1 to relax the supercoiled 
DNA. Hence, we performed WRN nuclear and TOPO1 co-expression analysis in the sporadic breast but there 
was no statistically significant associations with clinicopathological variables. 
Low WRN nuclear expression is associated with worse breast cancer specific survival 
In univariate analysis, patients whose tumour had low WRN nuclear expression had significantly (p=0.02) worse 
overall breast cancer-specific survival (BCSS) (Figure 2A). Furthermore, a statistically significant worse BCSS 
was observed in the ER-negative cohort (p=0.012) (Figure 2C). 
Low cytoplasmic WRN expression is associated with worse breast cancer specific survival 
Tumours with low WRN cytoplasmic expression had a poor BCSS which was statistically significant (p=0.017). 
There was no statistically significant impact on BCSS in ER+ and ER- cohorts (Figures 3D-3F). 
Low nuclear/cytoplasmic WRN co-expression is associated with poor breast cancer specific survival 
We then evaluated the impact of WRN nuclear and cytoplasmic co-expression on BCSS. In the whole cohort, 
patients with low nuclear/low cytoplasmic WRN expression had poor BCSS (p=0.04) suggesting that low 
expression has prognostic significance (Figure 3A). In the ER+ and ER- cohorts, WRN nuclear and cytoplasmic 
co-expression did not have any statistically significant impact on BCSS (Figure 3B & 3C).  
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Low WRN and high TOPO1 co-expression is associated with poor breast cancer specific survival 
In WRN nuclear and TOPO1 nuclear co-expression analysis, tumours with low WRN nuclear expression and high 
TOPO1 expression had poor BCSS in the whole cohort (Figure 3D). Nevertheless, there was no statistically 
significant impact on BCSS in the subgroup analysis. 
 
WRN nuclear and cytoplasmic expression are independent predictors of breast cancer specific survival 
In multivariate analysis (Table 4), WRN nuclear and cytoplasmic expression was independent prognostic factor 
for BCSS (p=0.039 and 0.032, respectively). Tumour stage and grade were also independently associated with 
BCSS. 
Discussion 
WRN is the largest family member of the human RECQ helicase protein.  WRN is the only DNA RECQ helicase 
that contains a nuclease domain and catalyses DNA-dependent reactions. WRN acts on various DNA structures 
to help with DNA repair through its enzymatic functions. Germline mutations in WRN leads to defects in DNA 
repair, premature aging and cancer susceptibility [21-23]. Genetic epidemiological studies identified certain 
polymorphisms of the WRN gene that are associated with increased risk of breast cancer [24-26]. Specifically, 
the CC genotype of WRN rs1346044 has been associated with the 2-fold risk of developing breast cancer [26]. In 
addition, a meta-analysis evaluated seven epidemiological studies and demonstrated that the CC genotype of 
Cys1367Arg polymorphism was also associated with 1.43 times increased risk of breast cancer [24]. A case-
control study in Chinese women that included approximately 4000 patients also showed that the variant genotype 
of WRN Leu1074Phe was associated with 1.36 times higher risk of breast cancer [25].  
We have previously shown, at transcriptomic level, that low WRN mRNA expression was associated with 
aggressive clinicopathological features such as high grade, lymph node stage and Her-2 overexpression and 
distinct aggressive molecular phenotypes as described by [27] including  PAM50.Her2, PAM50.LumB, Genufu 
subtype (ER+/Her2-/High proliferation) and Genufu subtype (Her2 positive) breast tumours [28]. Low WRN 
mRNA level was also associated with poor BCSS [28]. At the protein level, we observed complex staining patterns 
with tumours showing negative, nuclear and/or cytoplasmic WRN staining. Similar to the WRN mRNA 
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expression data [28], low cytoplasmic and low nuclear WRN protein levels were correlated to poor BCSS.  
However, low WRN protein expression was not significantly linked to clinicopathological characteristics. The 
mechanism of regulation of WRN expression is not clearly understood. It has been previously shown that 
epigenetic inactivation of WRN is common in solid tumours with the highest frequency in colorectal cancer 
[37.9% (69/182)] and a prevalence of 17.2% (10/58) in breast tumours [29].  Nevertheless, authors did not describe 
any clinicopathological associations in this study. In our previous study [28], we have found that WRN mRNA 
expression level was low in 326/1977 of breast tumours (16.5%) which are in accordance with the findings of 
with Agrelo et al study. 
Our findings indicate that low WRN expression in human tumours may lead to a ‘mutator phenotype’ expressed 
as aggressive breast cancers. Inactivation of WRN protein makes tumour cells susceptible to topoisomerase I 
poison and DNA-damaging agents. Cellular senescence is increased in WRN-deficient cells, in the presence of 
constant DNA damage and after treatment with chemotherapeutic agents such as Camptothecin [30-32]. In 
colorectal tumours, hypermethylation of WRN promoter CpG island was correlated with good response and better 
overall survival after treatment with irinotecan [29]. Specifically, WRN knockdown and Camptothecin treatment 
both induce DNA damage and cause increased p21 expression and SA-β-gal activity in colon cancer [30]. On the 
other hand, the rescue of WRN in tumour cells treated with Camptothecin enhanced the efficiency of DNA damage 
response to eliminate cytotoxic DNA lesions [28].  
In view of the interaction between WRN and TOPO1, we carried out combined WRN and TOPO1 analysis and 
showed that low WRN nuclear expression in TOPO1-overexpressed tumours is associated with worse BCSS. This 
is consistent with our previously published data at mRNA level where we demonstrated that low WRN expression 
in TOPO1-high tumours is associated with poor BCSS in the whole cohort [28]. Interestingly, at transcriptomic 
level, high WRN and high TOPO1 co-expression was associated with worse BCSS compared to low WRN and 
low TOPO1 co-expression in ER positive tumours. Nevertheless, this was not statistically significant at protein 
level. TOPO1 plays a vital role during replication and proliferation. We speculate that highly proliferative ER 
positive breast tumours (PAM50. Lum B phenotype) may be displaying endocrine resistance, hence leading to 
poor survival. As WRN is involved in various DNA repair pathways, it is possible that it promotes the DNA repair 
ability of established tumour cells to withstand DNA damage induced by endogenous and exogenous agents. A 
recent study identified NSC 19630 as a specific inhibitor of WRN, which synergistically inhibited cell 
proliferation and induced DNA damage with topotecan [33]. 
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In conclusion, we provide compelling evidence that WRN protein expression can influence the clinical outcomes 
in patients with sporadic breast cancer. We have also shown the prognostic significance of low WRN expression 
in TOPO1-overexpressed tumours as these patients might benefit from Topoisomerase I poisons. 
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Legends 
Table 1. Werner protein nuclear expression in sporadic breast cancer. 
Table 2. Werner protein cytoplasmic expression in sporadic breast cancer. 
Table 3. WRN protein nuclear and cytoplasmic co-expression in sporadic breast cancer. 
Table 4. Multivariate analysis of WRN protein expression in sporadic breast cancer. 
Figure 1. A) Western blot of WRN protein expression in breast cancer cell lines. B) Relative WRN protein 
expression in breast cancer cell lines. C) Microphotographs of WRN protein expression in normal breast tissue. 
D) Microphotographs of WRN protein expression in breast tumours. 
Figure 2. Kaplan-Meier curves showing BCSS in WRN nuclear and cytoplasmic expression at protein level. 
Figure 3. A-C. Kaplan-Meier curves showing BCSS in WRN nuclear and cytoplasmic co-expression at protein 
level. D. Kaplan-Meier curve showing BCSS in WRN and TOPO1 co-expression at protein level. 
Table 1. Werner protein nuclear expression in sporadic breast cancer. 
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Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
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1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
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1 (small-regular uniform) 
2 (Moderate variation) 





















Mixed NST/lobular/Special Type 
 








































B) Aggressive Phenotype 
 












































C) Hormone Receptors 





























































































































































































































































































































































































Abbreviations: Bold: Statistically significant; WRN: Werner; HER2: Human Epidermal Growth Factor Receptor 
2; NPI: Nottingham Prognostic Index; ER: oestrogen receptor; PgR: progesterone receptor; Triple negative: ER-
/PgR-/HER2-. Adjusted p values were calculated using Benjamini-Hochberg false discovery rate method to adjust 
for multiple testing. 
Table 2.  Werner protein cytoplasmic expression in sporadic breast cancer. 
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B) Aggressive Phenotype 
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Abbreviations: Bold: Statistically significant; WRN: Werner; HER2: Human Epidermal Growth Factor Receptor 
2; NPI: Nottingham Prognostic Index; ER: oestrogen receptor; PgR: progesterone receptor; Triple negative: ER-
/PgR-/HER2-. Adjusted p values were calculated using Benjamini-Hochberg false discovery rate method to adjust 
for multiple testing. 















































































































































































Table 3. WRN protein nuclear and cytoplasmic co-expression in sporadic breast cancer. 
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1 (>75% definite tubule) 
2 (10%-75% definite tubule) 






















Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 




























































































B) Aggressive Phenotype 






























































C) Hormone Receptors 









































A) DNA Repair Proteins 










































































































































































































































































B) Cell Cycle and Apoptosis Regulators 
 


































































































































































































































Abbreviations: Bold: Statistically significant; WRNn: Werner (nuclear); WRNc: Werner (cytoplasmic); HER2: Human Epidermal Growth Factor Receptor 2; 
NPI: Nottingham Prognostic Index; ER: oestrogen receptor; PgR: progesterone receptor; Triple negative: ER-/PgR-/HER2-. Adjusted p values were calculated 
using Benjamini-Hochberg false discovery rate method to adjust for multiple testing. 
 
Table 4. Multivariate analysis of WRN protein expression in sporadic 
breast cancer. 
 P value Exp (B) 95% CI of Exp (B) 
Lower Upper 
Breast Cancer Specific Survival 
Stage <0.001 1.954 1.442 2.649 
Grade <0.001 2.473 1.636 3.738 
HER2 overexpression 0.242 1.313 0.832 2.073 
NPI 0.531 0.793 0.383 1.639 
WRN (Cytoplasmic) 0.039 0.677 0.467 0.980 
WRN (Nuclear) 0.032 0.672 0.466 0.967 
TOPO1 (Nuclear) 0.270 1.234 0.849 1.794 




Figure 1. A) Western blot of WRN protein expression in breast cancer cell lines. B) Relative WRN protein 
expression in breast cancer cell lines. C) Microphotographs of WRN protein expression in normal breast tissue. D) 
Microphotographs of  WRN protein expression in breast tumours.
N-/C- (Nuclear negative & cytoplasmic negative); N+/C+ (Nuclear negative & cytoplasmic positive); N+/C- (Nuclear positive & 








DCIS Low grade Normal Duct
Intralobular Duct Normal Breast Acini
Whole cohort ER- cohort; NPI>3.4ER+ cohort; NPI>3.4B CA
WRN protein nuclear expression 
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Figure 2. Kaplan-Meier curves showing BCSS in WRN nuclear and cytoplasmic  expression at protein level.
Whole cohort ER+ cohort ER- cohort
WRN nuclear and cytoplasmic co-expression 
B CA
Figure 3. A-C. Kaplan-Meier curves showing BCSS in WRN nuclear and cytoplasmic  co-expression at protein level. 
D. Kaplan-Meier curve showing BCSS in WRN  and TOPO1 co-expression at protein level. 
D
Supplementary Table S1. Clinicopathological characteristics of Nottingham Tenovus series. 
Variable n* Cases          (%) 
Menopausal status 1650  
Pre-menopausal  612          (37.0) 
postmenopausal  1038        (63.0) 
Tumour Grade (NGS) 1650  
G1   306          (18.5) 
G2  531          (32.2) 
G3   813          (49.3) 
Lymph node stage 1650  
Negative   1056         (64.0) 
Positive (1-3 nodes)  486          (29.5) 
Positive (>3 nodes)  108           (6.5) 
Tumour size (cm) 1650  
T1 a + b (≤1.0)  187         (11.0) 
T1 c (>1.0 -2.0)  868         (53.0) 
T2 (>2.0-5)  579      (35.0) 
T3 (>5)  16         (1.0) 
Tumour type 1650  
IDC-NST  941         (57) 
Tubular   349         (21) 
ILC  160        (10) 
Medullary (typical/atypical)  41          (2.5) 
Others  159        (9.5) 
NPI subgroups 1650  
Excellent PG(2.08-2.40) Low risk 207         (12.5) 
Good PG(2.42-3.40) 331          (20.1) 
Moderate I PG(3.42 to 4.4) High risk 488         (29.6) 
Moderate II PG(4.42 to 5.4) 395         (23.9) 
Poor PG(5.42 to 6.4) 170         (10.3) 
Very poor PG(6.5–6.8) 59         (3.6) 
Survival at 20 years 1650  
Alive and well  1055         (64.0) 
Dead from disease  468          (28.4) 
Dead from other causes  127         (7.6) 
Adjuvant systemic therapy (AT)   
No AT   665         (42.0) 
Hormone therapy (HT)  642         (41.0) 
Chemotherapy  307         (20.0) 
Hormone + chemotherapy  46         (3.0) 
* Number of cases for which data were available. 
NPI; Nottingham prognostic index, PG; prognostic group 
Supplemental Table S2. Clinicopathological characteristics of ER- cohort. 
Variable n* Cases          (%) 
Menopausal status 252  
Pre-menopausal  122      (48.5) 
postmenopausal  130      (51.5) 
Tumour Grade (NGS) 252  
G1     1         (0.3) 
G2    27        (10.6) 
G3  224        (89.1) 
Lymph node stage 252  
Negative    121       (48) 
Positive (1-3 nodes)     86       (34) 
Positive (>3 nodes)      45      (18) 
Tumour size (cm) 252  
T1 a + b (≤1.0)   28        (11) 
T1 c (>1.0 -2.0)  106       (42) 
T2 (>2.0-5)  103       (41) 
T3 (>5)   15       (6) 
Tumour type 252  
IDC-NST  224        (89.0) 
Tubular   5            (2.0) 
ILC  8            (3.0) 
Medullary (typical/atypical)  5            (2.0) 
Others  0            (4.0) 
NPI subgroups 252  
Excellent PG(2.08-2.40) Low risk 0           (0.0) 
Good PG(2.42-3.40) 0           (0.0) 
Moderate I PG(3.42 to 4.4) High risk 111       (44.0) 
Moderate II PG(4.42 to 5.4) 81         (32.0) 
Poor PG(5.42 to 6.4) 38         (15.0) 
Very poor PG(6.5–6.8) 22         (9.0) 
Survival at 5 years 252  
Alive and well  176      (70.0) 
Dead from disease    73      (29.0) 
Dead from other causes     3       (1.0) 
* Number of cases for which data were available. 
NPI; Nottingham prognostic index, PG; prognostic group 
 
Supplementary Table and Figure legends 
Supplementary Table 1: Clinicopathological characteristics of Nottingham Tenovus series. 
Supplementary Table 2. Clinicopathological characteristics of ER- cohort. 
 
